BioPharma Resources

Drug Trial Radar · NCT05987449

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Dec 11, 2033

Study completion Dec 11, 2033

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.

Conditions

  • Hemophilia A

Interventions

  • NXT007Drug

    Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Grading ScaleTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
  2. Number of Participants with at Least One Clinical Laboratory Test Abnormality for Hematology ParametersTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
  3. Number of Participants with at Least One Clinical Laboratory Test Abnormality for Blood Chemistry ParametersTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
  4. Number of Participants with at Least One Vital Sign AbnormalityTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)
  5. Number of Participants with at Least One Abnormality on Electrocardiogram (ECG) RecordingsTime frame: From Baseline until study completion or discontinuation (up to 7.5 years)

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • UC Davis Cancer Center

    Sacramento, California · Recruiting

  • Georgetown Uni Medical Center

    Washington D.C., District of Columbia · Withdrawn

  • Indiana Hemophilia & Thrombosis center

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clnics Dept of Pediatrics

    Iowa City, Iowa · Recruiting

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Hamilton Health Sciences Corporation

    Hamilton, Ontario, Canada · Recruiting

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano (MI), Lombardy, Italy · Recruiting

  • Auckland Cancer Trial Centre

    Auckland, New Zealand · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland · Recruiting

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland · Recruiting

  • Hospital Universitario la Paz

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario Carlos Haya

    Málaga, Spain · Active not recruiting

  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.